Solid state forms of soquelitinib and process for preparation thereof
Crystalline polymorphs of Soquelitinib, characterized by XRPD and NMR, address the need for improved formulation by offering enhanced stability and dissolution, benefiting cancer treatment.
Patent Information
- Application Number
- PCT/IB2026/054490
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-11-25
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for additional salts and solid state forms of Soquelitinib, including solvated forms, to improve formulation characteristics such as stability, dissolution profile, and bioavailability, which are not adequately addressed by existing forms.
The development of crystalline polymorphs of Soquelitinib, including anhydrous and solvated forms, which are characterized by specific XRPD and solid state NMR patterns, and their use in pharmaceutical compositions for oral administration.
The crystalline polymorphs provide improved stability, handling, and dissolution properties, enhancing the effectiveness of Soquelitinib in treating cancers like T-cell lymphoma.
Smart Images

Figure IB2026054490_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket: API109-W001 (2222-244 PCT)SOLID STATE FORMS OF SOQUELITINIB AND PROCESS FOR PREPARATION THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of, and priority to, Indian Provisional Application No. 202511043947 filed on May 6, 2025; Indian Provisional Application No.202511080921 filed on August 26, 2025; Indian Provisional Application No. 202511088600 filed on September 17, 2025; and Indian Provisional Application No. 202511116965 filed on November 25, 2025. The entire contents of the foregoing applications are incorporated by reference herein.FIELD OF THE DISCLOSURE
[0002] The present disclosure encompasses solid state forms of Soquelitinib, in embodiments crystalline polymorphs of Soquelitinib, processes for preparation thereof, and pharmaceutical compositions thereof.BACKGROUND OF THE DISCLOSURE
[0003] Soquelitinib, A-[5-[4-methoxy-2-methyl-5-[(3^)-3-methyl-4-prop-2-enoyl-l,4-diazepane- 1 -carbonyl]phenyl] sulfanyl - 1 ,3 -thiazol -2-y l]cyclopropanecarboxamide, has the following structure:1 d" V uA
[0004] Soquelitinib is an orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK). It is currently in clinical trials for oncology and immunology indications. In particular, it is in phase III trial for the treatment of T-cell lymphoma. The compound is described in U.S. Patent No. 11,897,874. The entire contents of the foregoing patent are incorporated by reference herein.
[0005] Polymorphism, the occurrence of different crystalline forms, is a property of some molecules and molecular complexes. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by thermogravimetric analysis (“TGA”), or differentialAttorney Docket: API109-W001 (2222-244 PCT)scanning calorimetry (“DSC”)), X-ray diffraction (XRD) pattern, infrared absorption fingerprint, and solid state (13C) NMR spectrum. One or more of these techniques may be used to distinguish different polymorphic forms of a compound.
[0006] Different salts and solid state forms (including solvated forms) of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts and solid state forms and solvates may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, changing the dissolution profile in a favorable direction, or improving stability (polymorph as well as chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also offer improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms and solvates of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.
[0007] Discovering new salts, solid state forms and solvates of a pharmaceutical product may yield materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms. New solid state forms of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, including a different crystal habit, higher crystallinity, or polymorphic stability, which may offer better processing or handling characteristics, improved dissolution profile, or improved shelf-life (chemi cal / phy si cal stability). For at least these reasons, there is a need for additional salts and solid state forms (including solvated forms) of Soquelitinib.SUMMARY OF THE DISCLOSURE
[0008] The present disclosure provides crystalline polymorphs of Soquelitinib, processes for preparation thereof, and pharmaceutical compositions thereof. These crystalline polymorphs can be used to prepare other solid state forms of Soquelitinib, other Soquelitinib salts and co-crystals and their solid state forms.Attorney Docket: API109-W001 (2222-244 PCT)
[0009] The present disclosure also provides uses of the said solid state forms of Soquelitinib in the preparation of other solid state forms of Soquelitinib, or other salts or cocrystals of Soquelitinib and solid state forms thereof.
[0010] The present disclosure provides solid state forms of Soquelitinib for use in medicine, including for the treatment of cancer, such as solid tumors and hematological cancers. In embodiments, the cancer is T-cell lymphoma.
[0011] The present disclosure also encompasses the use of crystalline polymorphs of Soquelitinib of the present disclosure for the preparation of pharmaceutical compositions and / or formulations, particularly pharmaceutical compositions or formulations for oral administration.
[0012] In another aspect, the present disclosure provides pharmaceutical compositions comprising crystalline polymorphs of Soquelitinib according to the present disclosure. Pharmaceutical compositions according to any aspect of the present disclosure may include oral dosage forms.
[0013] The present disclosure includes processes for preparing the above mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Soquelitinib or mixtures thereof with at least one pharmaceutically acceptable excipient. Particularly, the pharmaceutical compositions may comprise pharmaceutically acceptable excipient suitable for preparing an oral dosage form.
[0014] The crystalline polymorphs of Soquelitinib as defined herein and the pharmaceutical compositions or formulations of the crystalline polymorphs of Soquelitinib may be used as medicaments, such as for the treatment of cancer, including solid tumors and hematological cancers.
[0015] The present disclosure also provides methods of treatment of cancer by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Soquelitinib of the present disclosure, or at least one of the above pharmaceutical compositions, to a subject in need thereof. In embodiments, the cancer is selected from solid tumors and hematological cancers. In further embodiments, the cancer is T-cell lymphoma.
[0016] The present disclosure also provides uses of the crystalline polymorphs of Soquelitinib of the present disclosure, or at least one of the above pharmaceutical compositions, for the manufacture of medicaments for treating cancer, including solid tumors and hematological cancers. In embodiments, the cancer is T-cell lymphoma. The medicament may be administered as an oral dosage form.Attorney Docket: API109-W001 (2222-244 PCT)BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ1.
[0018] FIG. 2 shows a characteristic X-ray powder diffraction pattern (XRPD) of amorphous Soquelitinib.
[0019] FIG. 3 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ2.
[0020] FIG. 4 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ3.
[0021] FIG. 5 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ4.
[0022] FIG. 6 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ5.
[0023] FIG. 7 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ6.
[0024] FIG. 8 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ7.
[0025] FIG. 9 shows a characteristic X-ray powder diffraction pattern (XRPD) of crystalline Soquelitinib - Form SQ8.
[0026] Fig. 10a shows solid state13C NMR spectrum of Soquelitinib Form SQ1 (full scan)
[0027] Fig. 10b shows solid state13C NMR spectrum of Soquelitinib Form SQ1 (range 0-100 ppm)
[0028] Fig. 10c shows solid state13C NMR spectrum of Soquelitinib Form SQ1 (range 100-200 ppm)
[0029] Fig Ila shows solid state13C NMR spectrum of Soquelitinib Form SQ3 (full scan)
[0030] Fig. 1 lb shows solid state13C NMR spectrum of Soquelitinib Form SQ3 (range 0-100 ppm)
[0031] Fig. 11c shows solid state13C NMR spectrum of Soquelitinib Form SQ3 (range 100-200 ppm)
[0032] Fig. 12a shows solid state13C NMR spectrum of Soquelitinib Form SQ8 (full scan)
[0033] Fig. 12b shows solid state13C NMR spectrum of Soquelitinib Form SQ8 (range 0-100 ppm)Attorney Docket: API109-W001 (2222-244 PCT)
[0034] Fig. 12c shows solid state13C NMR spectrum of Soquelitinib Form SQ8 (range 100-200 ppm)
[0035] Fig. 13 shows Differential Scanning Calorimetry (DSC) of Soquelitinib Form SQ4.DETAILED DESCRIPTION OF THE DISCLOSURE
[0036] The present disclosure encompasses solid state forms of Soquelitinib, including crystalline polymorphs of Soquelitinib, processes for preparation thereof, and pharmaceutical compositions thereof.
[0037] Solid state properties of Soquelitinib and crystalline polymorphs thereof can be influenced by controlling the conditions under which Soquelitinib and crystalline polymorphs thereof are obtained in solid form.
[0038] The solid-state form may be referred to herein as "Soquelitinib Form Name" or "Crystalline Form Name of Soquelitinib " or "Crystalline Soquelitinib Form Name" or "Crystalline polymorph Name of Soquelitinib " or "Crystalline Soquelitinib polymorph Name" or " Soquelitinib polymorph Name" . For example, crystalline Form SQ1 of Soquelitinib may be interchangeably referred to herein as Soquelitinib Form SQ1 or as Crystalline Soquelitinib Form SQ1 or as Crystalline polymorph SQ1 of Soquelitinib or as Crystalline Soquelitinib polymorph SQ1 or Soquelitinib polymorph SQ1.
[0039] As used herein, the terms ‘about’ and ‘approximately’ refer to variations that would be understood by one of ordinary skill in the art as being acceptable for the particular value or measurement, including variations associated with experimental error, instrument variability, rounding, and ordinary process variation.
[0040] A solid-state form (or polymorph) may be referred to herein as polymorphically pure or as substantially free of any other solid state (or polymorphic) forms. As used herein in this context, the expression "substantially free of any other forms" will be understood to mean that the solid state form contains about 20% (w / w) or less, about 10% (w / w) or less, about 5% (w / w) or less, about 2% (w / w) or less, about 1% (w / w) or less, or about 0% of any other forms of the subject compound as measured, for example, by XRPD. Thus, a crystalline polymorph of Soquelitinib described herein as substantially free of any other solid state forms would be understood to contain greater than about 80% (w / w), greater than about 90% (w / w), greater than about 95% (w / w), greater than about 98% (w / w), greater than about 99% (w / w), or about 100% of the subject crystalline polymorph of Soquelitinib. In some embodiments of the disclosure, the described crystalline polymorph of Soquelitinib may contain from about 1% toAttorney Docket: API109-W001 (2222-244 PCT)about 20% (w / w), from about 5% to about 20% (w / w), or from about 5% to about 10% (w / w) of one or more other crystalline polymorphs of the same Soquelitinib.
[0041] A compound may be referred to herein as chemically pure or purified compound or as substantially free of any other compounds. As used herein in this context, the expression "substantially free of any other compounds" will be understood to mean that the pure compound contains about 20% (w / w) or less, about 10% (w / w) or less, about 5% (w / w) or less, about 2% (w / w) or less, about 1% (w / w) or less, or about 0% of any other compound as measured, for example, by HPLC. Thus, pure or purified Soquelitinib, described herein as substantially free of any compounds would be understood to contain greater than about 80% (w / w), greater than about 90% (w / w), greater than about 95% (w / w), greater than about 98% (w / w), greater than about 99% (w / w), or about 100% of the subject Soquelitinib. In some embodiments of the disclosure, the described pure or purified Soquelitinib may contain from about 1% to about 20% (w / w), from about 5% to about 20% (w / w), or from about 5% to about 10% (w / w) of one or more other compounds.
[0042] In specific embodiments, the above described pure or purified Soquelitinib may relate to enantiomeric purity, i.e. pure or purified Soquelitinib refers to Soquelitinib that is substantially free of enantiomers of Soquelitinib.
[0043] Depending on which other crystalline polymorphs a comparison is made, the crystalline polymorphs of Soquelitinib of the present disclosure may have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability, such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and / or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility and bulk density.
[0044] A solid state form, such as a crystal form or an amorphous form, may be referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra. As is well-known in the art, the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called “fingerprint”) which cannot necessarily be described by reference to numerical values or peak positions alone. In any event, the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to certain factors such as, but not limited to, variations in instrument response and variations in sampleAttorney Docket: API109-W001 (2222-244 PCT)concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with graphical data generated for an unknown crystal form and confirm whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms. A crystal form of Soquelitinib referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure will thus be understood to include any crystal forms of Soquelitinib, characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure.
[0045] As used herein, and unless stated otherwise, the term “anhydrous” in relation to crystalline forms of Soquelitinib, relates to a crystalline form of Soquelitinib which does not include any crystalline water (or other solvents) in a defined, stoichiometric amount within the crystal. Moreover, unless otherwise indicated, an “anhydrous” form would generally not contain more than 1% (w / w), of either water or organic solvents as measured for example by TGA.
[0046] The term "solvate", as used herein and unless indicated otherwise, refers to a crystal form that incorporates a solvent in the crystal structure. When the solvent is water, the solvate is often referred to as a "hydrate". The solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.
[0047] As used herein, the term "isolated" in reference to crystalline polymorph of Soquelitinib of the present disclosure corresponds to a crystalline polymorph of Soquelitinib that is physically separated from the reaction mixture, in which it is formed.
[0048] As used herein, unless stated otherwise, the XRPD measurements are taken using copper Ka radiation wavelength 1.54187 A. XRPD peaks reported herein are measured using CuK a radiation, = 1.54187 A, typically at a temperature of 25 ± 3°C.
[0049] A thing, e.g., a reaction mixture, may be characterized herein as being at, or allowed to come to “room temperature” or “ambient temperature,” often abbreviated as “RT ” This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located. Typically, room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.
[0050] The amount of solvent employed in a chemical process, e.g., a reaction or crystallization, may be referred to herein as a number of “volumes” or “vol” or “V.” For example, a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a solvent. In this context, this expression would be understood to mean milliliters of theAttorney Docket: API109-W001 (2222-244 PCT)solvent per gram of the material being suspended, such that suspending 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent. In another context, the term "v / v" may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v / v) to a 100 ml reaction mixture would indicate that 150 mL of solvent X was added.
[0051] A process or step may be referred to herein as being carried out "overnight." This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, in some cases about 16 hours.
[0052] As used herein, the term “reduced pressure” refers to a pressure that is less than atmospheric pressure. For example, reduced pressure is about 10 mbar to about 50 mbar.
[0053] As used herein and unless indicated otherwise, the term "ambient conditions" refer to atmospheric pressure and a temperature of 22-24°C.
[0054] The present disclosure includes a crystalline polymorph of Soquelitinib, designated Form SQ1. Crystalline Form SQ1 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 7.4, 11.7, 14.5, 19.2 and 21.3 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 1; or by combinations thereof.
[0055] Crystalline Form SQ1 may be further characterized by an XRPD pattern having characteristic peaks at 7.4, 11.7, 14.5, 19.2 and 21.3 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three or four additional peaks at 9.3, 13.3, 18.6 and 20.5 degrees 2-theta ± 0.2 degrees 2-theta.
[0056] Crystalline Form SQ1 may be described by an XRPD pattern having characteristic peaks at 7.4, 9.3, 11.7, 13.3, 14.5, 18.6, 19.2, 20.5 and 21.3 degrees 2-theta ± 0.2 degrees 2-theta.
[0057] In any embodiment of the present disclosure crystalline Form SQ1 of Soquelitinib may alternatively or additionally be characterized by a solid state13C NMR spectrum having peaks at 16.0, 30.7, 44.2, 57.3, 149.1 and 153.1 ppm ± 0.2 ppm. Crystalline Form SQ1 may alternatively or additionally be characterized by solid state13C NMR spectrum having the following chemical shift absolute differences from a peak at 39.9 ppm ± 2 ppm of 23.9, 9.2, 4.3, 17.4, 109.2 and 113.2 ppm ± 0.1 ppm. Crystalline Form SQ1 may alternatively or additionally be characterized by solid state13C NMR spectrum having chemical shift differenceAttorney Docket: API109-W001 (2222-244 PCT)from a peak at 16.0 ppm ± 1 ppm of 23.9 ppm ± 0.1 ppm. Crystalline Form SQ1 may alternatively or additionally be characterized by a solid state13C NMR spectrum substantially as depicted in any of Figures 10a, 10b or 10c, preferably Figure 10a.
[0058] According to any aspect or embodiment of the present disclosure, crystalline Form SQ1 of Soquelitinib is preferably isolated.
[0059] In certain embodiments, crystalline Form SQ1 of Soquelitinib may be an anhydrous form.
[0060] Crystalline Form SQ1 of Soquelitinib may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 7.4, 11.7, 14.5, 19.2 and 21.3 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 1, and combinations thereof.
[0061] According to any aspect or embodiment of the disclosure, crystalline Form SQ1 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0062] According to any aspect or embodiment of the disclosure, crystalline Form SQ1 of Soquelitinib is a stable upon exposure to humidity, heat and grinding. Crystalline Form SQ1 is stable upon exposure to humidity (20%, 40%, 60%, 80% and 100%) at RT for at least 7 days. Crystalline Form SQ1 is stable under accelerated conditions (40°C / 75%RH) for at least 3 months. Crystalline Form SQ1 is stable under heating (100°C). Crystalline Form SQ1 is stable upon dry or solvent drop grinding (water, ethanol or isopropanol).
[0063] The present disclosure also discloses a crystalline polymorph of Soquelitinib, designated Form SQ2. Crystalline Form SQ2 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 6.6, 11.1, 15.6, 17.1 and 22.3 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 3; or by combinations thereof.
[0064] Crystalline Form SQ2 may be further characterized by an XRPD pattern having characteristic peaks at 6.6, 11.1, 15.6, 17.1 and 22.3 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, or three additional peaks at 18.2, 19.0 and 20.5 degrees 2-theta ± 0.2 degrees 2-theta.
[0065] Crystalline Form SQ2 may be described by an XRPD pattern having characteristic peaks at 6.6, 11.1, 15.6, 17.1, 18.2, 19.0, 20.5 and 22.3 degrees 2-theta ± 0.2 degrees 2-theta.
[0066] According to any aspect or embodiment of the present disclosure, crystalline Form SQ2 of Soquelitinib is preferably isolated.Attorney Docket: API109-W001 (2222-244 PCT)
[0067] In certain embodiments, Crystalline Form SQ2 of Soquelitinib may be a solvated form. In embodiment, vinyl acetate solvated form.
[0068] Crystalline Form SQ2 of Soquelitinib may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 6.6, 11.1, 15.6, 17.1 and 22.3 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 3, and combinations thereof.
[0069] According to any aspect or embodiment of the disclosure, crystalline Form SQ2 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0070] The present disclosure includes a crystalline polymorph of Soquelitinib, designated Form SQ3. Crystalline Form SQ3 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 4.1, 11.3, 15.8, 17.5 and 20.3 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 4; or by combinations thereof.
[0071] Crystalline Form SQ3 may be further characterized by an XRPD pattern having characteristic peaks at 4.1, 11.3, 15.8, 17.5 and 20.3 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two or three additional peaks at 12.0, 13.0 and 22.7 degrees 2-theta ± 0.2 degrees 2-theta.
[0072] Crystalline Form SQ3 may be described by an XRPD pattern having characteristic peaks at 4.1, 11.3, 12.0, 13.0, 15.8, 17.5, 20.3 and 22.7 degrees 2-theta± 0.2 degrees 2-theta.
[0073] In any embodiment of the present disclosure crystalline Form SQ3 of Soquelitinib may alternatively or additionally be characterized by a solid state13C NMR spectrum having peaks at 13.5, 20.4, 119.0, 143.2, 144.4 and 154.7 ppm ± 0.2 ppm. Crystalline Form SQ3 may alternatively or additionally be characterized by solid state13C NMR spectrum having the following chemical shift absolute differences from a peak at 39.7 ppm ± 2 ppm of 26.2, 19.3, 79.3, 103.5, 104.7 and 115.0 ppm ± 0.1 ppm. Crystalline Form SQ3 may alternatively or additionally be characterized by solid state13C NMR spectrum having chemical shift difference from a peak at 13.5 ppm ± 1 ppm of 26.2 ppm ± 0.1 ppm. Crystalline Form SQ3 may alternatively or additionally be characterized by a solid state13C NMR spectrum substantially as depicted in any of Figures Ila, 1 lb or 11c, preferably Figure Ila.
[0074] According to any aspect or embodiment of the present disclosure, crystalline Form SQ3 of Soquelitinib is preferably isolated.
[0075] In certain embodiments, Crystalline Form SQ3 of Soquelitinib may be an anhydrous form. Crystalline Form SQ3 of Soquelitinib may be characterized by each of the aboveAttorney Docket: API109-W001 (2222-244 PCT)characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 4.1, 11.3, 15.8, 17.5 and 20.3 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 4, and combinations thereof.
[0076] According to any aspect or embodiment of the disclosure, crystalline Form SQ3 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0077] According to any aspect or embodiment of the disclosure, crystalline Form SQ3 of Soquelitinib is a stable upon exposure to humidity, heat and grinding. Crystalline Form SQ3 is stable upon exposure to humidity (20%, 40%, 60%, 80% and 100%) at RT for at least 7 days. Crystalline Form SQ3 is stable under accelerated conditions (40°C / 75%RH) for at least 3 months. Crystalline Form SQ3 is stable under heating (100°C). Crystalline Form SQ3 is stable to dry or solvent drop grinding (water, ethanol or isopropanol).
[0078] The present disclosure also discloses a crystalline polymorph of Soquelitinib, designated Form SQ4. Crystalline Form SQ4 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 8.0, 9.6, 22.2, 23.0 and 25.3 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 5; or by combinations thereof.
[0079] Crystalline Form SQ4 may be further characterized by an XRPD pattern having characteristic peaks at 8.0, 9.6, 22.2, 23.0 and 25.3 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, or three additional peaks at 6.2, 17.4 and 18.3 degrees 2-theta ± 0.2 degrees 2-theta.
[0080] Crystalline Form SQ4 may be described by an XRPD pattern having characteristic peaks at 6.2, 8.0, 9.6, 17.4, 18.3, 22.2, 23.0 and 25.3 degrees 2-theta ± 0.2 degrees 2-theta.
[0081] In any embodiment of the present disclosure crystalline Form SQ4 of Soquelitinib may alternatively or additionally be characterized by Differential Scanning Calorimetry (DSC). Crystalline Form SQ4 shows an endothermic peak at 190.78°C. The high melting point indicates that crystalline Form SQ4 is thermodynamically stable.
[0082] According to any aspect or embodiment of the present disclosure, crystalline Form SQ4 of Soquelitinib is preferably isolated.
[0083] In certain embodiments, Crystalline Form SQ4 of Soquelitinib may be anhydrous form.
[0084] Crystalline Form SQ4 of Soquelitinib may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks atAttorney Docket: API109-W001 (2222-244 PCT)8.0, 9.6, 22.2, 23.0 and 25.3 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 5, and combinations thereof.
[0085] According to any aspect or embodiment of the disclosure, crystalline Form SQ4 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0086] The present disclosure includes a crystalline polymorph of Soquelitinib, designated Form SQ5. Crystalline Form SQ5 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 9.3, 11.1, 14.8, 15.7 and 16.9 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 6; or by combinations thereof.
[0087] Crystalline Form SQ5 may be further characterized by an XRPD pattern having characteristic peaks at 9.3, 11.1, 14.8, 15.7 and 16.9 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three or four additional peaks at 6.7, 19.4, 20.6 and 22.3 degrees 2-theta ± 0.2 degrees 2-theta.
[0088] Crystalline Form SQ5 may be described by an XRPD pattern having characteristic peaks at 6.7, 9.3, 11.1, 14.8, 15.7, 16.9, 19.4, 20.6 and 22.3 degrees 2-theta ± 0.2 degrees 2-theta.
[0089] According to any aspect or embodiment of the present disclosure, crystalline Form SQ5 of Soquelitinib is preferably isolated.
[0090] In certain embodiments, Crystalline Form SQ5 of Soquelitinib may be a hydrate; preferably sesqui hydrate.
[0091] Crystalline Form SQ5 of Soquelitinib may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 9.3, 11.1, 14.8, 15.7 and 16.9 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 6, and combinations thereof.
[0092] According to any aspect or embodiment of the disclosure, crystalline Form SQ5 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0093] According to any aspect or embodiment of the disclosure, crystalline Form SQ5 of Soquelitinib is a stable upon exposure to humidity, heat and grinding. Crystalline Form SQ5 is stable upon exposure to humidity (20%, 40%, 60%, 80% and 100%) at RT for at least 7 days. Crystalline Form SQ5 is stable under heating (100°C). Crystalline Form SQ5 is stable to dry or solvent drop grinding (water, ethanol or isopropanol).Attorney Docket: API109-W001 (2222-244 PCT)
[0094] The present disclosure provides also a crystalline polymorph of Soquelitinib, designated Form SQ6. Crystalline Form SQ6 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 8.2, 10.6, 13.5, 21.8 and 23.5 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 7; or by combinations thereof.
[0095] Crystalline Form SQ6 may be further characterized by an XRPD pattern having characteristic peaks at 8.2, 10.6, 13.5, 21.8 and 23.5 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three or four additional peaks at 6.8, 12.8, 15.4 and 20.7 degrees 2-theta ± 0.2 degrees 2-theta.
[0096] Crystalline Form SQ6 may be described by an XRPD pattern having characteristic peaks at 6.8, 8.2, 10.6, 12.8, 13.5, 15.4, 20.7, 21.8 and 23.5 degrees 2-theta ± 0.2 degrees 2-theta.
[0097] According to any aspect or embodiment of the present disclosure, crystalline Form SQ6 of Soquelitinib is preferably isolated.
[0098] In certain embodiments, Crystalline Form SQ6 of Soquelitinib may be an anhydrous form.
[0099] Crystalline Form SQ6 of Soquelitinib may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 8.2, 10.6, 13.5, 21.8 and 23.5 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 7, and combinations thereof.
[0100] According to any aspect or embodiment of the disclosure, crystalline Form SQ6 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0101] The present disclosure includes a crystalline polymorph of Soquelitinib, designated Form SQ7. Crystalline Form SQ7 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 12.0, 13.0, 15.2, 15.9 and 22.7 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 8; or by combinations thereof.
[0102] Crystalline Form SQ7 may be further characterized by an XRPD pattern having characteristic peaks at 12.0, 13.0, 15.2, 15.9 and 22.7 degrees 2-theta± 0.2 degrees 2-theta, and also having any one, two or three additional peaks at 6.5, 11.3 and 13.8 degrees 2-theta ± 0.2 degrees 2-theta.
[0103] Crystalline Form SQ7 may be described by an XRPD pattern having characteristic peaks at 6.5, 11.3, 12.0, 13.0, 13.8, 15.2, 15.9 and 22.7 degrees 2-theta ± 0.2 degrees 2-theta.Attorney Docket: API109-W001 (2222-244 PCT)
[0104] According to any aspect or embodiment of the present disclosure, crystalline Form SQ7 of Soquelitinib is preferably isolated.
[0105] In certain embodiments, Crystalline Form SQ7 of Soquelitinib may be a hydrate form; preferably a dihydrate form.
[0106] Crystalline Form SQ7 of Soquelitinib may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 12.0, 13.0, 15.2, 15.9 and 22.7 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 8, and combinations thereof.
[0107] According to any aspect or embodiment of the disclosure, crystalline Form SQ7 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0108] The present disclosure provides also a crystalline polymorph of Soquelitinib, designated Form SQ8. Crystalline Form SQ8 may be described by data selected from one or more of the following: an XRPD pattern having characteristic peaks at 12.1, 14.9, 16.2, and 16.9 degrees 2-theta ± 0.2 degrees 2-theta, or by an XRPD pattern as depicted in FIG. 9; or by combinations thereof.
[0109] Crystalline Form SQ8 may be further characterized by an XRPD pattern having characteristic peaks at 12.1, 14.9, 16.2 and 16.9 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, or three additional peaks at 20.3, 21.9 and 22.6 degrees 2-theta ± 0.2 degrees 2-theta.
[0110] Crystalline Form SQ8 may be described by an XRPD pattern having characteristic peaks at 12.1, 14.9, 16.2, 16.9, 20.3, 21.9 and 22.6 degrees 2-theta ± 0.2 degrees 2-theta.
[0111] In any embodiment of the present disclosure crystalline Form SQ8 of Soquelitinib may alternatively or additionally be characterized by a solid state13C NMR spectrum having peaks at 40.7, 50.5, 51.5, 117.6, 160.9 and 174.7 ppm ± 0.2 ppm. Form SQ8 may alternatively or additionally be characterized by solid state13C NMR spectrum having the following chemical shift absolute differences from a peak at 128.1 ppm ± 2 ppm of 87.4, 77.6, 76.6, 10.5, 32.8 and 46.6 ppm ± 0.1 ppm. Form SQ8 may alternatively or additionally be characterized by solid state13C NMR spectrum having chemical shift difference from a peak at 40.7 ppm ± 1 ppm of 87.4 ppm ± 0.1 ppm. Form SQ8 may alternatively or additionally be characterized by a solid state13C NMR spectrum substantially as depicted in any of Figures 12a, 12b or 12c, preferably Figure 12a.
[0112] According to any aspect or embodiment of the present disclosure, crystalline Form SQ8 of Soquelitinib is preferably isolated.Attorney Docket: API109-W001 (2222-244 PCT)
[0113] In certain embodiments, Crystalline Form SQ8 of Soquelitinib may be a hydrated form; preferably, monohydrate.
[0114] Crystalline Form SQ8 of Soquelitinib may be characterized by each of the above characteristics alone / or by all possible combinations, e.g., an XRPD pattern having peaks at 12.1, 14.9, 16.2 and 16.9 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in FIG. 9, and combinations thereof.
[0115] According to any aspect or embodiment of the disclosure, crystalline Form SQ8 of Soquelitinib may be polymorphically pure or may be substantially free of any other solid-state forms of Soquelitinib.
[0116] According to any aspect or embodiment of the disclosure, crystalline Form SQ8 of Soquelitinib is a stable upon exposure to humidity, heat and grinding. Crystalline Form SQ8 is stable upon exposure to humidity (20%, 40%, 60%, 80% and 100%) at RT for at least 7 days. Crystalline Form SQ8 is stable under heating (100°C). Crystalline Form SQ8 is stable to dry or solvent drop grinding (water, ethanol or isopropanol).
[0117] The above crystalline polymorphs can be used to prepare other crystalline polymorphs of Soquelitinib, other Soquelitinib salts or co-crystals and their solid-state forms. Solid state forms may be crystalline polymorphs, co-crystals and complexes of Soquelitinib or of Soquelitinib salt.
[0118] The present disclosure encompasses a process for preparing other solid-state forms of Soquelitinib or of Soquelitinib salts. The process includes preparing any one of the crystalline polymorphs of Soquelitinib by the processes of the present disclosure. The process may further comprise converting said crystalline polymorph of Soquelitinib to other crystalline polymorph of Soquelitinib or to other Soquelitinib salt or co-crystal.
[0119] The present disclosure provides the above-described crystalline polymorphs of Soquelitinib for use in the preparation of pharmaceutical compositions comprising Soquelitinib and / or crystalline polymorphs thereof.
[0120] The present disclosure also encompasses the use of crystalline polymorphs of Soquelitinib of the present disclosure for the preparation of pharmaceutical compositions of crystalline polymorph Soquelitinib. Particularly, the pharmaceutical compositions may be used for oral administration.
[0121] The present disclosure includes processes for preparing the above-mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Soquelitinib of the present disclosure with at least one pharmaceutically acceptable excipient. Particularly, the pharmaceutical compositions mayAttorney Docket: API109-W001 (2222-244 PCT)comprise pharmaceutically acceptable excipient suitable for making formulations for oral administration. In addition to the active ingredient, the pharmaceutical formulations of the present disclosure can contain one or more excipients. Excipients are added to the formulation for a variety of purposes. For example, excipients may be added to assist in formation of formulation suitable for oral administration.
[0122] Diluents increase the bulk of a solid pharmaceutical composition and can make a pharmaceutical dosage form containing the composition easier for the patient and caregiver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
[0123] Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, can include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, and starch.
[0124] The dissolution rate of a compacted solid pharmaceutical composition in the patient’s stomach can be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., Explotab®), and starch.
[0125] Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.Attorney Docket: API109-W001 (2222-244 PCT)
[0126] When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and dye. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
[0127] Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present disclosure include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
[0128] Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and / or facilitate patient identification of the product and unit dosage level.
[0129] In liquid pharmaceutical compositions of the present disclosure, Soquelitinib and any other solid excipients can be dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.
[0130] Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that can be useful in liquid compositions of the present disclosure include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
[0131] Liquid pharmaceutical compositions of the present disclosure can also contain a viscosity enhancing agent to improve the mouthfeel of the product and / or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, xanthan gum and combinations thereof.
[0132] Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar can be added to improve the taste.Attorney Docket: API109-W001 (2222-244 PCT)
[0133] Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid can be added at levels safe for ingestion to improve storage stability.
[0134] According to the present disclosure, a liquid composition can also contain a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate. Selection of excipients and the amounts used can be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
[0135] The solid compositions of the present disclosure include powders, granulates, aggregates, and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, intranasal and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, in embodiments the route of administration is oral. The dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
[0136] Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and lozenges, as well as liquid syrups, suspensions, and elixirs.
[0137] The dosage form of the present disclosure can be a capsule containing the composition, such as a powdered or granulated solid composition of the disclosure, within either a hard or soft shell. The shell can be made from gelatin and optionally contain a plasticizer such as glycerin and / or sorbitol, an opacifying agent and / or colorant.
[0138] The active ingredient and excipients can be formulated into compositions and dosage forms according to methods known in the art.
[0139] A composition for tableting or capsule filling can be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water that causes the powders to clump into granules. The granulate is screened and / or milled, dried, and then screened and / or milled to the desired particle size. The granulate can then be tableted, or other excipients can be added prior to tableting, such as a glidant and / or a lubricant.
[0140] A tableting composition can be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can subsequently be compressed into a tablet.Attorney Docket: APH09-W001 (2222-244 PCT)
[0141] As an alternative to dry granulation, a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate, and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
[0142] A capsule filling of the present disclosure can include any of the aforementioned blends and granulates that were described with reference to tableting, but they are not subjected to a final tableting step.
[0143] A pharmaceutical formulation of Soquelitinib can be administered. For example, it can be administered orally. Soquelitinib may be formulated for administration to a mammal, in embodiments to a human. Soquelitinib can be formulated, for example, as a viscous liquid solution or suspension, such as a clear solution, for injection. The formulation can contain one or more solvents. A suitable solvent can be selected by considering the solvent’s physical and chemical stability at various pH levels, viscosity (which would allow for syringeability), fluidity, boiling point, miscibility, and purity. Suitable solvents include alcohol USP, benzyl alcohol NF, benzyl benzoate USP, and Castor oil USP. Additional substances can be added to the formulation such as buffers, solubilizers, and antioxidants, among others. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7thed.
[0144] The crystalline polymorph of Soquelitinib and the pharmaceutical compositions and / or formulations of Soquelitinib of the present disclosure can be used as medicaments, in embodiments for the treatment of cancer, including solid tumors and hematological cancers. In embodiments, the cancer is T-cell lymphoma. The medicament may preferably be administered in oral form.
[0145] Having thus described the disclosure with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the disclosure as described and illustrated that do not depart from the spirit and scope of the disclosure as disclosed in the specification. The Examples are set forth to aid in understanding the disclosure but are not intended to, and should not be construed to limit its scope in any way.Powder X-ray Diffraction ("XRPD") method
[0146] Powder X-ray Diffraction was performed on an X-Ray powder diffractometer:Attorney Docket: APH09-W001 (2222-244 PCT)Bruker D8 Advance; Copper Ka radiation ( = 1.5418 A); Lynx eye detector; laboratory temperature 22-25 °C; PMMA specimen holder ring. Prior to analysis, the samples were gently ground by means of mortar and pestle in order to obtain a fine powder. The ground sample was adjusted into a cavity of the sample holder and the surface of the sample was smoothed by means of a cover glass.
[0147] All X-Ray Powder Diffraction peak values are calibrated with regard to standard silicon spiking in the sample.Measurement parameters:Scan range: 2 - 40 degrees 2-theta;Scan mode: continuous;Step size: 0.05 degrees;Time per step: 0.5 s;Sample spin: 30 rpm;Sample holder: PMMA specimen holder ring.Solid state13C-NMR (ss13C-NMR)
[0148] The solid-state NMR spectra are measured at 11.7 T using a Bruker Avance III HD 500 US / WB NMR spectrometer (Karlsruhe, Germany, 2013) with a 4-mm probehead.
[0149] The samples (as received) were placed into the 4-mm thin-wall ZrO2 rotor.
[0150] The13C CP / MAS NMR spectra employing cross-polarization were acquired using the standard cross-polarization pulse scheme at spinning frequency of 11 kHz. The cross-polarization contact time was 2 ms, and the dipolar decoupling SPINAL64 was applied during the data acquisition. The spectral width was 300 ppm with the resonance offset of 100 ppm. The13C scale was referenced to a-glycine (176.03 ppm for13C).
[0151] The 1H MAS NMR spectra employing a single-pulse excitation were measured at spinning frequency of 11 kHz using a 1H (90 degree) pulse of 4 ps and power level 88 W. The number of scans was 4 (NS=4). The 1H scale was referenced to a-glycine (8.5 ppm for NH3+ signal).
[0152] The 1H T1 spin-lattice relaxation buildup spectra were recorded to optimize DI repetition delay using a variable repetition delay (Dl=0.5, 1, 2, 4, 8, 16, 32 and 64 s). The number of scans was 1 (NS=1) and the number of dummy scans used for saturation was 4 (DS=4).Attorney Docket: API109-W001 (2222-244 PCT)
[0153] The experiments were carried out with active cooling, keeping the samples at a constant temperature of 280K.Differential Scanning Calorimetry (DSC) Method:
[0154] DSC was performed using a TA instrument Q2000 differential scanning calorimetry. About 1.5 mg sample was accurately weighed into an aluminum pan without lid. The sample cell was equilibrated at 20°C and heated at a rate of 10°C / min up to 250°C under the nitrogen atmosphere.EXAMPLESPreparation of starting materials
[0155] Soquelitinib can be prepared according to methods known from the literature, for example U.S. Patent No. 11,897,874.Example 1: Preparation of crystalline Soquelitinib - Form SQ1
[0156] Soquelitinib (0.03 g, amorphous) was dissolved in 1 mL of dichloromethane at 25°C. The clear solution was added to 5 mL of n-Heptane kept at 25°C and the reaction mixture was stirred at 25°C for 15 hours. The obtained solid was filtered and dried in vacuum tray drier at 25°C for 2 hours. The obtained solid was analyzed by XRD and designated as Form SQ1, as shown in FIG. 1.Example 2: Preparation of amorphous Soquelitinib
[0157] Soquelitinib (0.05 g) was dissolved in dichloromethane (10 mL) at 55°C. The clear solution was subjected to distillation under high vacuum (below 50 mbar) on rotary evaporator at 40°C for about 30-45 minutes. The solid was isolated and was analyzed by XRD and designated as amorphous form, as shown in FIG. 2.Example 3: Preparation of crystalline Soquelitinib - Form SQ2
[0158] Soquelitinib (Form SQ1, 20 mg) was suspended in vinyl acetate (0.5 mL) at 25°C. The reaction mixture was stirred and heated to 65°C during 80 minutes. After heating, the reaction mixture was gradually cooled to -5°C during 150 minutes. The reaction mass was then subjected to six thermal cycles between -5°C and 65°C, with a controlled temperature ramp of 0.5°C per minute. Upon completion of the thermal cycling, the mixture was brought back to 25°C. The reaction mixture was filtered and dried under vacuum for 10-15 minutes. The obtained solid was analyzed by XRD and designated as Form SQ2, as shown in FIG. 3.Attorney Docket: API109-W001 (2222-244 PCT)Example 4: Preparation of crystalline Soquelitinib - Form SQ3
[0159] Soquelitinib (Form SQ2, 0.05g) was charged in a glass vial. Petroleum ether (2 ml) was added and the obtained slurry was heated up to 100°C and maintained under stirring for about 16 hours at about 100°C. The reaction mass was brought to room temperature, filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ3; as shown in FIG. 4.Example 5: Preparation of crystalline Soquelitinib - Form SQ4
[0160] Soquelitinib (Form SQ2, 0.05g) was charged in a glass vial. Diisopropyl ether (DIPE; 2ml) was added and the obtained slurry was heated up to 80°C and maintained under stirring for about 16 hours. The reaction mixture was brought to room temperature, filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ4; as shown in Fig. 5.Example 6: Preparation of crystalline Soquelitinib - Form SQ5
[0161] Soquelitinib (0.1 g, Amorphous) was dissolved in ethyl formate (2 mL) at 25°C. The clear solution was added to water (10 mL) and the mixture was then stirred for 15 hours at 25°C. The solid was filtered and dried in a vacuum tray drier (VTD) at 25°C for 2 hours. The obtained solid was analyzed by XRD and designated as Form SQ5; as shown in Figure 6. Example 7: Preparation of crystalline Soquelitinib - Form SQ5
[0162] Soquelitinib (0.02g, Form SQ6) was suspended in a mixture of water: methanol (9:1, 0.5 mL) at 25°C. The reaction mixture was stirred at 25°C for 16 hours, the solid was filtered and dried under vacuum at 25°C for 30 minutes. The obtained solid was analyzed by XRD and designated as Form SQ5.Example 8: Preparation of crystalline Soquelitinib - Form SQ6
[0163] Soquelitinib (Form SQ5, 0.03 g) was dried under vacuum at 70°C for 16 hours in a vacuum tray drier (VTD). The sample was cooled down to about 25 °C. The solid was analyzed by XRD and designated as Form SQ6; as shown in Figure 7.Example 9: Preparation of crystalline Soquelitinib - Form SQ7
[0164] Soquelitinib (Form SQ1, 2 g) was charged in a glass vial. A mixture of ethyl lactate and water (1:9; 30ml) was added and the obtained slurry was stirred 16 hours at about 25°C. The reaction mass was filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ7; as shown in Figure 8.Example 10: Preparation of crystalline Soquelitinib - Form SQ8
[0165] Soquelitinib (Amorphous, 0.1 g) was charged in a glass vial. Diethyl carbonate (3 ml) was added and the slurry was stirred for 2-3 hours at about 25°C. The reaction mixture wasAttorney Docket: API109-W001 (2222-244 PCT)filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ8; as shown in Figure 9.Example 11: Preparation of amorphous Soquelitinib
[0166] Soquelitinib (0.5 g) was dissolved in Dichloromethane (50 mL) at 40°C. The clear solution was subjected to distillation under high vacuum (below 50 mbar) on rotary evaporator at 40°C for about 30-45 minutes. The solid was isolated and was analyzed by XRD and designated as amorphous form.Example 12: Preparation of crystalline Soquelitinib - Form SQ1
[0167] Soquelitinib (Amorphous, 0.02g) was charged in a glass vial. Added 0.5ml of cyclohexane and the slurry mass was heated up to 100°C and maintained under stirring for about 16 hours at about 100°C. The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ1.Example 13: Preparation of crystalline Soquelitinib - Form SQ1
[0168] Soquelitinib (Amorphous, 0.02g) was charged in a glass vial. Added 0.5ml of heptane and slurry mass was heated up to 100°C and maintained under stirring for about 16 hours at about 100°C. The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ1.Example 14: Preparation of crystalline Soquelitinib - Form SQ1
[0169] Soquelitinib (Amorphous, 0.02g) was charged in a glass vial. Added 0.5ml of hexane and slurry mass was heated up to 100°C and maintained under stirring for about 16 hours at about 100°C. The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ1.Example 15: Preparation of crystalline Soquelitinib - Form SQ2
[0170] Soquelitinib (Form SQ1, 1g) was dissolved in Vinyl acetate (25 mL) at 60°C. After heating, the clear solution was gradually cooled to -10°C for 15 minutes and maintained for 24 hour at -10°C. The reaction mixture was filtered and dried under vacuum for 10-15 minutes. The solid was isolated and analyzed by XRD and designated as Form SQ2.Example 16: Preparation of crystalline Soquelitinib - Form SQ3
[0171] Soquelitinib (Form SQ2, 0.5g) was charged in a glass vial. Added 20ml petroleum ether and slurry mass was heated up to 100°C and maintained under stirring for about 16 hoursAttorney Docket: API109-W001 (2222-244 PCT)at about 100°C.The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ3.Example 17: Preparation of crystalline Soquelitinib - Form SQ3
[0172] Soquelitinib (Form SQ1, 0.02g) was charged in a glass vial. Added 0.4ml of DMSO: water mixture (10:90) and slurry mass was stirred for about 12 hours at about 25°C. The reaction mass was filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ3.Example 18: Preparation of crystalline Soquelitinib - Form SQ3
[0173] Soquelitinib (Form SQ5, 0.02g) was charged in a glass vial. Added 0.4ml of Ethanol : water mixture (10:90) and slurry mass was stirred for about 12 hours at about 65°C. The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ3.Example 19: Preparation of crystalline Soquelitinib - Form SQ3
[0174] Soquelitinib (Form SQ6, 0.02g) was charged in a glass vial. Added 0.3ml of Acetone : water mixture (10:90) and slurry mass was stirred for about 12 hours at about 65°C. The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ3.Example 20: Preparation of crystalline Soquelitinib - Form SQ3
[0175] Soquelitinib (Form SQ7, 0.02g) was charged in a glass vial. Added 0.3ml of THF:water mixture (10:90) and slurry mass was stirred for about 12 hours at about 65°C. The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ3.Example 21: Preparation of crystalline Soquelitinib - Form SQ3
[0176] Soquelitinib (Amorphous, 0.02g) was charged in a glass vial. Added 0.5ml of diisopropyl ether and slurry mass was heated up to 100°C and maintained under stirring for about 16 hours at about 100°C. The reaction mass was brought to room temperature and filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ3.Example 22: Preparation of crystalline Soquelitinib - Form SQ5
[0177] Soquelitinib (2 g, Amorphous) was dissolved in 40 mL of ethyl formate at 25°C. The clear solution added to 200 mL of water kept at 25°C and the reaction mass maintained at 25°C for 24 hours. Solid obtained was filtered and dried in Vacuum tray drier at 25°C for 2 hours. The obtained solid analyzed by XRD and designated as Form SQ5.Attorney Docket: API109-W001 (2222-244 PCT)Example 23: Preparation of crystalline Soquelitinib - Form SQ6
[0178] Soquelitinib Form SQ5 (1 g) was dried under vacuum at 70°C for 16 hours in Vacuum tray drier (VTD). The sample was cooled down to about 25 °C. The solid was analyzed by XRD and designated as Form SQ6.Example 24: Preparation of crystalline Soquelitinib - Form SQ8
[0179] Soquelitinib (Amorphous, 1 g) was charged in a glass vial. Diethyl carbonate (30 mL) was added, and the reaction mass was slurried at about 25°C with stirring for about 2-3 hours. The reaction mass was filtered and dried under vacuum for 20-25 minutes. The obtained solid was analyzed by XRD and designated as Form SQ8.Example 25: Stability Experiments
[0180] Samples of crystalline Forms SQ1, SQ3, SQ5, and SQ8 of Soquelitinib were exposed to different relative humidity (%RH) at RT for 7 days. The samples were analyzed by XRD before and after exposure to relative humidity. The results are summarized in Table 1.Table 1Initial 20% RH 40% RH 60% RH 80% RH 100% RH 77 days 7 days 7 days 7 days days SQ1 SQ1 SQ1 SQ1 SQ1 SQ1 SQ3 SQ3 SQ3 SQ3 SQ3 SQ3 SQ5 SQ5 SQ5 SQ5 SQ5 SQ5SQ8 SQ8 SQ8 SQ8 SQ8 SQ8
[0181] Crystalline Forms SQ1, SQ3, SQ5, and SQ8 of Soquelitinib are stable upon exposure to different humidity conditions (20%, 40%, 60%, 80% and 100% RH) at RT for at least 7 days.
[0182] Samples of crystalline Forms SQ1, SQ3, SQ5, and SQ8 of Soquelitinib were heated to 100°C for 30 min in an air tray dryer (ATD). The samples were analyzed by XRD before and after heating. The results are summarized in Table 2.Table 2100°C @ ATDInitial30 min.SQ1 SQ1SQ3 SQ3SQ5 SQ5SQ8 SQ8Attorney Docket: API109-W001 (2222-244 PCT)
[0183] Crystalline Forms SQ1, SQ3, SQ5, and SQ8 of Soquelitinib are stable to heating up to 100°C.
[0184] Samples of crystalline Forms SQ1, SQ3, SQ5, SQ6, and SQ8 of Soquelitinib were exposed to strong grinding with a mortar and pestle in dry and wet conditions (solvent drop water, ethanol or isopropanol). The samples were analyzed by XRD before and after grinding. The results are summarized in Table 3.Table 3Initial Strong Water drop Ethanol IPA drop Grinding Grinding drop grinding grindingSQ1 SQ1 SQ1 SQ1 SQ1 SQ3 SQ3 SQ3 SQ3 SQ3 SQ5 SQ5 SQ5 SQ5 SQ5 SQ6 SQ6 SQ5 SQ5 SQ5SQ8 SQ8 SQ8 SQ8 SQ8
[0185] Crystalline Forms SQ1, SQ3, SQ5, and SQ8 of Soquelitinib are stable to dry or solvent drop grinding (water, ethanol or isopropanol). Crystalline Form SQ6 is stable to dry grinding.
[0186] Samples of crystalline Form SQ1 and SQ3 of Soquelitinib were exposed to different temperatures (25°C and 40°C) and humidity (RH of 60% and 75%) for 1, 2 and 3 months. The samples were analyzed by XRD before and after exposure to the different temperatures and humidity. The results are shown in Table 4.Table 4Initial form Month Condition Form (XRD)25°C 60%RH SQ1IM40°C 75%RH SQ125°C 60%RH SQ1SQ1 2M40°C 75%RH SQ125°C 60%RH SQ13M40°C 75%RH SQ125°C 60%RH SQ3IM40°C 75%RH SQ325°C 60%RH SQ3SQ3 2M40°C 75%RH SQ325°C 60%RH SQ33M40°C 75%RH SQ3Attorney Docket: API109-W001 (2222-244 PCT)
[0187] Crystalline Forms SQ1 and SQ3 of Soquelitinib are stable at accelerated conditions (40°C and 75% RH) for at least 3 months.
Claims
Attorney Docket: API109-W001 (2222-244 PCT)Claims1. A crystalline form SQ1 of Soquelitinib characterized by data including at least one of:a) an XRPD pattern having peaks at: 7.4, 11.7, 14.5, 19.2 and 21.3 degrees 2-theta ± 0.2 degrees 2-theta;b) an XRPD pattern as depicted in Figure 1;c) a solid state13C NMR spectrum having peaks at: 16.0, 30.7, 44.2, 57.3, 149.1 and 153.1 ppm ± 0.2 ppm;d) a solid state13C NMR spectrum having the following chemical shift absolute differences from a peak at 39.9 ppm ± 2 ppm of 23.9, 9.2, 4.3, 17.4, 109.2 and 113.2 ppm ± 0.1 ppm; ore) a solid-state13C NMR spectrum substantially as depicted in Figures 10a, 10b, or 10c.
2. The crystalline form SQ1 of Soquelitinib according to Claim 1, which is characterized by an XRPD pattern having peaks at: 7.4, 11.7, 14.5, 19.2 and 21.3 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, three, or four additional peaks selected from: 9.3, 13.3, 18.6 and 20.5 degrees 2-theta ± 0.2 degrees 2-theta.
3. The crystalline form SQ1 of Soquelitinib according to any of Claims 1 and 2, which is characterized by an XRPD pattern having peaks at: 7.4, 9.3, 11.7, 13.3, 14.5, 18.6, 19.2, 20.5 and 21.3 degrees 2-theta ± 0.2 degrees 2-theta.
4. The crystalline form SQ1 of Soquelitinib according to any of Claims 1, 2, and 3, which is isolated.
5. The crystalline form SQ1 of Soquelitinib according to any of Claims 1, 2, 3 and 4, which is anhydrous.
6. A crystalline form SQ3 of Soquelitinib characterized by data including at least one of: a) an XRPD pattern having peaks at: 4.1, 11.3, 15.8, 17.5 and 20.3 degrees 2-theta ± 0.2 degrees 2-theta;b) an XRPD pattern as depicted in Figure 4;c) a solid state13C NMR spectrum having peaks at: 13.5, 20.4, 119.0, 143.2, 144.4 and 154.7 ppm ± 0.2 ppm;d) a solid state13C NMR spectrum having the following chemical shift absolute differences from a peak at 39.7 ppm ± 2 ppm of 26.2, 19.3, 79.3, 103.5, 104.7 and 115.0 ppm ± 0.1 ppm; orAttorney Docket: API109-W001 (2222-244 PCT)e) a solid-state13C NMR spectrum substantially as depicted in Figures 1 la, 1 lb, or 11c.
7. The crystalline form SQ3 of Soquelitinib according to Claim 6, which is characterized by an XRPD pattern having peaks at: 4.1, 11.3, 15.8, 17.5 and 20.3 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, or three, additional peaks selected from: 12.0, 13.0 and 22.7 degrees 2-theta ± 0.2 degrees 2-theta.
8. The crystalline form SQ3 of Soquelitinib according to any of Claims 6 and 7, which is characterized by an XRPD pattern having peaks at: 4.1, 11.3, 12.0, 13.0, 15.8, 17.5, 20.3 and 22.7 degrees 2-theta ± 0.2 degrees 2-theta.
9. The crystalline form SQ3 of Soquelitinib according to any of Claims 6, 7, and 8, which is isolated.
10. The crystalline form SQ3 of Soquelitinib according to any of Claims 6, 7, 8, and 9, which is anhydrous.
11. A crystalline form SQ8 of Soquelitinib characterized by data including at least one of: a) an XRPD pattern having peaks at: 12.1, 14.9, 16.2, and 16.9 degrees 2-theta ± 0.2 degrees 2-theta;b) an XRPD pattern as depicted in Figure 9;c) a solid state13C NMR spectrum having peaks at: 40.7, 50.5, 51.5, 117.6, 160.9 and 174.7 ppm ± 0.2 ppm;d) a solid state13C NMR spectrum having the following chemical shift absolute differences from a peak at 128.1 ppm ± 2 ppm of 87.4, 77.6, 76.6, 10.5, 32.8 and 46.6 ppm ± 0.1 ppm; ore) a solid-state13C NMR spectrum substantially as depicted in Figures 12a, 12b, or 12c.
12. The crystalline form SQ8 of Soquelitinib according to Claim 11, which is characterized by an XRPD pattern having peaks at: 12.1, 14.9, 16.2 and 16.9 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, or three, additional peaks selected from: 20.3, 21.9 and 22.6 degrees 2-theta ± 0.2 degrees 2-theta.
13. The crystalline form SQ8 of Soquelitinib according to any of Claims 11 and 12, which is characterized by an XRPD pattern having peaks at: 12.1, 14.9, 16.2, 16.9, 20.3, 21.9 and 22.6 degrees 2-theta ± 0.2 degrees 2-theta.
14. The crystalline form SQ8 of Soquelitinib according to any of Claims 11, 12 and 13, which is isolated.Attorney Docket: API109-W001 (2222-244 PCT)15. The crystalline form SQ8 of Soquelitinib according to any of Claims 11, 12, 13 and 14, which is a hydrated form, preferably a monohydrate.
16. A crystalline form SQ4 of Soquelitinib characterized by data including at least one of: a) an XRPD pattern having peaks at: 8.0, 9.6, 22.2, 23.0 and 25.3 degrees 2-theta ± 0.2 degrees 2-theta;b) an XRPD pattern as depicted in Figure 5;c) a DSC with an endothermic peak at about 190.8 °C; ord) a DSC as depicted in Fig. 13.
17. The crystalline form SQ4 of Soquelitinib according to Claim 16, which is characterized by an XRPD pattern having peaks at: 8.0, 9.6, 22.2, 23.0 and 25.3 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, or three, additional peaks selected from: 6.2, 17.4 and 18.3 degrees 2-theta ± 0.2 degrees 2-theta.
18. The crystalline form SQ4 of Soquelitinib according to any of Claims 16 and 17, which is characterized by an XRPD pattern having peaks at: 6.2, 8.0, 9.6, 17.4, 18.3, 22.2, 23.0 and 25.3 degrees 2-theta ± 0.2 degrees 2-theta.
19. The crystalline form SQ4 of Soquelitinib according to any of Claims 16, 17 and 18, which is isolated.
20. The crystalline form SQ4 of Soquelitinib according to any of Claims 16, 17, 18 and 19, which is anhydrous.
21. A pharmaceutical composition comprising the crystalline form of Soquelitinib according to any of Claims 1 to 20.
22. A pharmaceutical formulation comprising the crystalline form of Soquelitinib according to any of Claims 1 to 20, or a pharmaceutical composition of Claim 21, with at least one pharmaceutically acceptable excipient.
23. A process for preparing the pharmaceutical formulation according to Claim 22, comprising combining the crystalline form of Soquelitinib according to any of Claims 1 to 20, or the pharmaceutical composition of Claim 21, with at least one pharmaceutically acceptable excipient.
24. The crystalline form of Soquelitinib according to any of Claims 1 to 20, the pharmaceutical composition according to Claim 21, or the pharmaceutical formulation according to Claim 22, for use as a medicament.
25. The crystalline form of Soquelitinib according to any of Claims 1 to 20, the pharmaceutical composition according to Claim 21, or the pharmaceutical formulation according to Claim 22, for use in the treatment of T-cell lymphoma.Attorney Docket: API109-W001 (2222-244 PCT)26. A method of treating T-cell lymphoma, comprising administering a therapeutically effective amount of the crystalline form of Soquelitinib according to any of Claims 1 to 20, the pharmaceutical composition according to Claim 21, or the pharmaceutical formulation according to Claim 22, to a subject in need of the treatment.
27. The crystalline form of Soquelitinib according to any of Claims 1 to 20, the pharmaceutical composition according to Claim 21, or the pharmaceutical formulation according to Claim 22, for the manufacture of a medicament for treating T-cell lymphoma.
28. Use of the crystalline form of Soquelitinib according to any of Claims 1 to 20, in the preparation of other solid state forms of Soquelitinib, or other Soquelitinib salts and cocrystals and their solid state forms.
